Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional network
This preliminary real-world experience confirms that first-line Siltuximab is effective and well tolerated in patients with iMCD, achieving durable disease control in the majority of cases. These findings support the continued use of Siltuximab as the standard of care and underscore the importance of expanding real-world registries to better define the epidemiology and treatment outcomes of iMCD in Italy.
Authors
- Stefan Hohaus (ORCID: https://orcid.org/0000-0002-5534-7197)
- Agostino Tafuri
- Giulio Trapè
- Anna Giulia Zizzari
- Luigi Rigacci
- G. Pileggi
- A. Di Napoli
- G. Palumbo
- M. C. Cox
- M. Martelli
- L. Filomeno
- A. Di Rocco
- E. Maiolo
- G. La Verde
- S. Pelliccia
- M. P. Bianchi
- A. Rago
Institutions
- University of Rome Tor Vergata (IT)
- Università Campus Bio-Medico (IT)
- ASL Roma (IT)
- Azienda Ospedaliera Sant'Andrea (IT)
- Ospedale di Belcolle (IT)
- University of the Sacred Heart (JP)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-16
- DOI
- https://doi.org/10.3389/fonc.2026.1762473
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00